Login Register Cart 0
Generic placeholder image

Current Medical Imaging

Editor-in-Chief

ISSN (Print): 1573-4056
ISSN (Online): 1875-6603

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Gd-EOB-DTPA-enhanced Magnetic Resonance Imaging Combined with T1 Mapping Identifies Dysplastic Module and Hepatocellular Carcinoma: A Retrospective Study

Author(s): Diyou Chen, Qisheng Ran, Wei Ma, Huan Xie, Jie Zhou, Ji Liu, Yuanyuan Zhao, Letian Zhang* and Yu Guo*

Volume 20, 2024

Published on: 08 September, 2023

Article ID: e080823219533 Pages: 8

DOI: 10.2174/1573405620666230808153145

Price: $65

Abstract

Background: Hepatocellular carcinoma (HCC) is the leading type of liver cancer in adults, often resulting in fatal outcomes for those with cirrhosis. Dysplastic nodule (DN) is a liver nodule that is substantial in size, ranging from 1-2 cm. However, accurately distinguishing between DN and HCC on imaging has posed a challenge.

Objective: The aim of this study is to assess the usefulness of Gd-EOB-DTPA-enhanced MRI T1 mapping in distinguishing between DN and HCC.

Methods: This study analyzed 66 patients with confirmed HCC or DN who underwent Gd-EOB-DTPA-enhanced MRI T1 mapping before surgery or puncture at the Army Medical Center in China. The T1 values of each lesion were measured before and after Gd-EOB-DTPA administration, and various calculations were made, including absolute and percentage reduction in T1 value and coefficient of variation. The t-test was used to compare these values between the two groups, and the efficacy of T1 mapping values for differential diagnosis of HCC and DN was evaluated using the receiver operating characteristic curve (ROC).

Results: The study found that T1pre, T1hp, ΔT1, ΔT1%, and CV in the HCC group were significantly higher than in the DN group (p < 0.01). The accuracy of T1hp, ΔT1, and CVT1-hp in identifying HCC from DN was high, with AUCs of 0.955, 0.910, and 0.932, respectively. ΔT1% also had some accuracy, with an AUC of 0.818.

Conclusion: Our results provide preliminary evidence that Gd-EOB-DTPA-enhanced MRI T1 mapping, can be a valuable tool in diagnosing and differentiating between HCC and DN.

[1]
Villanueva A. Hepatocellular Carcinoma. N Engl J Med 2019; 380(15): 1450-62.
[http://dx.doi.org/10.1056/NEJMra1713263] [PMID: 30970190]
[2]
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71(3): 209-49.
[http://dx.doi.org/10.3322/caac.21660] [PMID: 33538338]
[3]
Henley SJ, Ward EM, Scott S, et al. Annual report to the nation on the status of cancer, part I: National cancer statistics. Cancer 2020; 126(10): 2225-49.
[http://dx.doi.org/10.1002/cncr.32802] [PMID: 32162336]
[4]
Trevisani F, Cantarini MC, Wands JR, Bernardi M. Recent advances in the natural history of hepatocellular carcinoma. Carcinogenesis 2008; 29(7): 1299-305.
[http://dx.doi.org/10.1093/carcin/bgn113] [PMID: 18515282]
[5]
Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42(5): 1208-36.
[http://dx.doi.org/10.1002/hep.20933] [PMID: 16250051]
[6]
Peng Z, Jiang M, Cai H, et al. Gd-EOB-DTPA-enhanced magnetic resonance imaging combined with T1 mapping predicts the degree of differentiation in hepatocellular carcinoma. BMC Cancer 2016; 16: 625.
[http://dx.doi.org/10.1186/s12885-016-2607-4]
[7]
Rao C, Wang X, Li M, Zhou G, Gu H. Value of T1 mapping on gadoxetic acid-enhanced MRI for microvascular invasion of hepatocellular carcinoma: a retrospective study. BMC Med Imaging 2020; 20(1): 43.
[http://dx.doi.org/10.1186/s12880-020-00433-y]
[8]
Di Martino M, Anzidei M, Zaccagna F, et al. Qualitative analysis of small (≤2 cm) regenerative nodules, dysplastic nodules and well-differentiated HCCs with gadoxetic acid MRI BMC Med Imaging 2016; 16(1): 62.
[http://dx.doi.org/10.1186/s12880-016-0165-5]
[9]
Kogita S, Imai Y, Okada M, et al. Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: Correlation with histological grading and portal blood flow. Eur Radiol 2010; 20(10): 2405-13.
[http://dx.doi.org/10.1007/s00330-010-1812-9] [PMID: 20490505]
[10]
Lee MH, Kim SH, Park MJ, Park CK, Rhim H. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease. AJR Am J Roentgenol 2011; 197(5): W868-75.
[http://dx.doi.org/10.2214/AJR.10.6237] [PMID: 22021534]
[11]
Horsthuis K, Nederveen AJ, de Feiter MW, Lavini C, Stokkers PCF, Stoker J. Mapping of T1-values and Gadolinium-concentrations in MRI as indicator of disease activity in luminal Crohn’s disease: A feasibility study. J Magn Reson Imaging 2009; 29(2): 488-93.
[http://dx.doi.org/10.1002/jmri.21535] [PMID: 19161209]
[12]
Heidenreich JF, Weng AM, Donhauser J, et al. T1- and ECV-mapping in clinical routine at 3 T: Differences between MOLLI, ShMOLLI and SASHA. BMC Med Imaging 2019; 19(1): 59.
[http://dx.doi.org/10.1186/s12880-019-0362-0]
[13]
Zhou ZP, Long LL, Qiu WJ, et al. Comparison of 10- and 20-min hepatobiliary phase images on Gd-EOB-DTPA-enhanced MRI T1 mapping for liver function assessment in clinic. Abdom Radiol 2017; 42(9): 2272-8.
[http://dx.doi.org/10.1007/s00261-017-1143-2] [PMID: 28396918]
[14]
Kellman P, Hansen MS. T1-mapping in the heart: Accuracy and precision. J Cardiovasc Magn Reson 2014; 16(1): 2.
[http://dx.doi.org/10.1186/1532-429X-16-2]
[15]
Chow K, Flewitt JA, Green JD, Pagano JJ, Friedrich MG, Thompson RB. Saturation recovery single-shot acquisition (SASHA) for myocardial T1 mapping. Magn Reson Med 2014; 71(6): 2082-95.
[http://dx.doi.org/10.1002/mrm.24878] [PMID: 23881866]
[16]
Weingärtner S, Akçakaya M, Basha T, et al. Combined saturation/inversion recovery sequences for improved evaluation of scar and diffuse fibrosis in patients with arrhythmia or heart rate variability. Magn Reson Med 2014; 71(3): 1024-34.
[http://dx.doi.org/10.1002/mrm.24761] [PMID: 23650078]
[17]
Fernandes JL, Rochitte CE. T1 Mapping. Magn Reson Imaging Clin N Am 2015; 23(1): 25-34.
[http://dx.doi.org/10.1016/j.mric.2014.08.007] [PMID: 25476671]
[18]
Okada M, Murakami T, Yada N, et al. Comparison between T1 relaxation time of Gd-EOB-DTPA-enhanced MRI and liver stiffness measurement of ultrasound elastography in the evaluation of cirrhotic liver. J Magn Reson Imaging 2015; 41(2): 329-38.
[http://dx.doi.org/10.1002/jmri.24529] [PMID: 24343840]
[19]
Yoon JH, Lee JM, Paek M, Han JK, Choi BI. Quantitative assessment of hepatic function: modified look-locker inversion recovery (MOLLI) sequence for T1 mapping on Gd-EOB-DTPA-enhanced liver MR imaging. Eur Radiol 2016; 26(6): 1775-82.
[http://dx.doi.org/10.1007/s00330-015-3994-7] [PMID: 26373756]
[20]
Yoon JH, Lee JM, Kim E, Okuaki T, Han JK. Quantitative liver function analysis: Volumetric T1 mapping with fast multisection B 1 inhomogeneity correction in hepatocyte-specific contrast-enhanced liver MR imaging. Radiology 2017; 282(2): 408-17.
[http://dx.doi.org/10.1148/radiol.2016152800] [PMID: 27697007]
[21]
Ding Y, Rao SX, Meng T, Chen C, Li R, Zeng MS. Usefulness of T1 mapping on Gd-EOB-DTPA-enhanced MR imaging in assessment of non-alcoholic fatty liver disease. Eur Radiol 2014; 24(4): 959-66.
[http://dx.doi.org/10.1007/s00330-014-3096-y] [PMID: 24463697]
[22]
Bae KE, Kim SY, Lee SS, et al. Assessment of hepatic function with Gd-EOB-DTPA-enhanced hepatic MRI. Dig Dis 2012; 30(6): 617-22.
[http://dx.doi.org/10.1159/000343092] [PMID: 23258104]
[23]
Qin XL, Huang ZK, Long LL, et al. The value of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid enhanced T1 mapping in dysplastic nodule and hepatocellular carcinoma with different degrees of differentiation. Zhonghua Fang She Xue Za Zhi 2018; 52(8): 5.
[24]
Kitao A, Matsui O, Yoneda N, et al. The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: Correlation with gadoxetic acid enhanced MR imaging. Eur Radiol 2011; 21(10): 2056-66.
[http://dx.doi.org/10.1007/s00330-011-2165-8] [PMID: 21626360]
[25]
Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115(2): 209-18.
[http://dx.doi.org/10.1172/JCI24282] [PMID: 15690074]
[26]
Haimerl M, Verloh N, Zeman F, et al. Assessment of clinical signs of liver cirrhosis using T1 mapping on Gd-EOB-DTPA-enhanced 3T MRI. PLoS One 2013; 8(12): 85658.
[http://dx.doi.org/10.1371/journal.pone.0085658]
[27]
Fujita N, Nishie A, Asayama Y, et al. Hyperintense liver masses at hepatobiliary phase gadoxetic acid–enhanced mrI: Imaging appearances and clinical importance. Radiographics 2020; 40(1): 72-94.
[http://dx.doi.org/10.1148/rg.2020190037] [PMID: 31834849]
[28]
Li Z, Bilgin A, Johnson K, et al. Rapid high-resolution T 1 mapping using a highly accelerated radial steady-state free-precession technique. J Magn Reson Imaging 2019; 49(1): 239-52.
[http://dx.doi.org/10.1002/jmri.26170] [PMID: 30142230]
[29]
Li Z, Fu Z, Keerthivasan M, et al. Rapid high-resolution volumetric T1 mapping using a highly accelerated stack-of-stars Look Locker technique. Magn Reson Imaging 2021; 79: 28-37.
[http://dx.doi.org/10.1016/j.mri.2021.03.003] [PMID: 33722634]
[30]
Feng L, Liu F, Soultanidis G, et al. Magnetization‐prepared GRASP MRI for rapid 3D T1 mapping and fat/water‐separated T1 mapping. Magn Reson Med 2021; 86(1): 97-114.
[http://dx.doi.org/10.1002/mrm.28679] [PMID: 33580909]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy